Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Chattem Eyes Diet Pill Profitability With Dexatrim MAX

This article was originally published in The Tan Sheet

Executive Summary

Chattem will launch Dexatrim MAX diet pills in early 2005 in an effort to boost sales of the sagging line of diet products

You may also be interested in...



Chattem Banks On “Best New Product Lineup” To Fuel 2006 Sales

Icy Hot and Selsun line extensions will drive 2006 top line growth in the 20-25% range and earnings growth to 10-15%, Chattem projects

Chattem Banks On “Best New Product Lineup” To Fuel 2006 Sales

Icy Hot and Selsun line extensions will drive 2006 top line growth in the 20-25% range and earnings growth to 10-15%, Chattem projects

Chattem Banks On “Best New Product Lineup” To Fuel 2006 Sales

Icy Hot and Selsun line extensions will drive 2006 top line growth in the 20-25% range and earnings growth to 10-15%, Chattem projects

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS097315

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel